Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis

Table 3 Change in gastroesophageal reflux disease-health related quality of life score from baseline at weeks 4 and 8 (per protocol set)

GERD-HRQL	Fexuprazan 40 mg			Esomeprazole 40 mg
	Baseline (n = 107)	Week 4 (n = 102)	Week 8 (n = 106)	Baseline (n = 111)	Week 4 (n = 104)	Week 8 (n = 111)
mean ± SD	11.88 ± 8.11	4.21 ± 6.17	4.01 ± 6.20	12.98 ± 9.62	3.42 ± 5.04	3.32 ± 5.54
Change from baseline (mean ± SD)	-	-7.71 ± 8.37	-7.90 ± 8.56	-	-9.84 ± 8.70	-9.67 ± 8.56
P value1	-	< 0.001w	< 0.001t	-	< 0.001w	< 0.001w
LS mean difference from esomeprazole	-	1.06	1.05	-	-	-
P value2	-	0.137	0.151	-	-	-

¹Testing for change within-treatment groups [paired t-test (t) or Wilcoxon signed rank test (w)].

²Testing for difference between treatment groups (ANCOVA model with treatment group as a factor, baseline score and stratification factor (baseline LA classification) as covariates).

Note: If subjects did not have any Gastroesophageal reflux disease-health related quality of life (GERD-HRQL) assessment data by week 4, were treated as missing at week 4. One subject in fexuprazan 40 mg did not have GERD-HRQL assessment data post baseline. GERD-HRQL: Gastroesophageal reflux disease-health related quality of life; LS mean: Least square mean.